"Prof. Dr. Ion Chiricuta" Institute of Oncology, Hematology Department

Cluj-Napoca 400015

1 studies enrolling now · 1 studies all time

What they study most

MF, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now